A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 349 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-23.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 4th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 89th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Two different groups of participants may enter into the study:
Rollover Participants
Participants who were not randomization-eligible at the end of the Run-in Period of lead-in studies RLM-MD-01 (NCT03285308) or RLM-MD-02 (NCT03426345) are eligible to be randomized in the study if all of the following criteria apply:
•In the lead-in studies, participants must have met all screening visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)) except that:
De Novo Participants
Exclusion Criteria:
Both Rollover and De Novo Participants
•Participants with a known allergy or to the study treatments and their (i.e., mannitol or phenol)
Rollover Participants
•Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at the Screening Visit and at the end of the Run-in Period for randomization into the Treatment Period of studies RLM-MD-01 and RLM-MD-02, except as specified in the inclusion criteria
De Novo Participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
Drug: Placebo
Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
Drug: Relamorelin
Placebo injected subcutaneously twice daily.
Relamorelin 10 μg injected subcutaneously twice daily.
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 12 of this study
Change From Baseline to Week 52 in the Weekly Average DGSSS
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02 for rollover participants or Day -14 to Day -1 for new participants) to Week 52 of this study
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Time frame: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks)
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to 52 weeks
Number of Participants With Clinically Meaningful Trends for Vital Signs
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
Time frame: Up to 52 weeks
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Time frame: Up to 52 weeks
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c)
Time frame: Up to 52 weeks
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
Time frame: Baseline (Day 1), Day 84, Day 364, and End of Treatment (Up to Day 364)
| Milestone | Placebo | Relamorelin 10 μg |
|---|---|---|
| Started | 148 | 302 |
| Safety population | 145 | 299 |
| Run-in period | 91 | 207 |
| Completed | 63 | 118 |
| Not completed | 85 | 184 |
| Withdrew: Screen failure | 1 | 0 |
| Withdrew: Adverse event | 6 | 18 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Withdrawal by subject | 20 | 36 |
| Withdrew: Lost to follow-up | 5 | 15 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 8 |
| Withdrew: Study terminated by the sponsor | 48 | 95 |
| Withdrew: Reason not specified | 4 | 6 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
| score on a scale | Placebo | Relamorelin 10 μg |
|---|---|---|
| Baseline | 20.3 ± 6.70 | 19.7 ± 6.39 |
| Change from Baseline to Week 12 | -7.1 ± 8.82 | -6.5 ± 7.80 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). The average weekly scores at Week 52 were the average of the DGSSS scores from Week 49 to Week 52. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous study or the run-in period of this study for new participants.
| score on a scale | Placebo | Relamorelin 10 μg |
|---|---|---|
| Baseline | 20.3 ± 6.70 | 19.7 ± 6.39 |
| Change from Baseline to Week 52 | -10.7 ± 8.93 | -8.6 ± 8.92 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | 105 | 221 |
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Hematocrit (RATIO): >1.1×Upper Limit of Normal Value (ULN) | 0 | 1 |
| Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN) | 5 | 14 |
| Hemoglobin (gram(g)/L): <0.9×LLN | 10 | 20 |
| Lymphocytes Absolute Cell Count (10^9/(Liter(L)): >1.5×ULN | 1 | 5 |
| Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN | 2 | 9 |
| Mean Corpuscular Volume [femtoliter(fL)]: >1.1×ULN | 2 | 2 |
| Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN | 2 | 0 |
| Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN | 7 | 3 |
| Red Blood Cell Count (10^12/L):<0.9×LLN | 2 | 10 |
| White Blood Cell Count (10^9/L): <0.7×LLN | 2 | 0 |
| Alanine Aminotransferase (Serum Glutamate-Pyruvate transaminase (SGPT)) (Unit (U)/L): ≥3.0×ULN | 0 | 6 |
| Albumin (gram (g)/L): <0.9×LLN | 0 | 1 |
| Alkaline Phosphatase (U/L): ≥3.0×ULN | 0 | 1 |
| Aspartate Aminotransferase (Serum Glutamic-Oxaloacetic Transaminase (SGOT)) (U/L): ≥3.0×ULN | 2 | 3 |
| Bicarbonate (HCO3) (millimole (mmol)/L): >1.1×ULN | 3 | 2 |
| Bicarbonate (HCO3) (millimole (mmol)/L): >1.1×LLN | 3 | 2 |
| Bicarbonate (HCO3) (millimole (mmol)/L): <0.9×LLN | 6 | 6 |
| Bilirubin, Total (micromole (umol)/L): >1.5×ULN | 0 | 1 |
| Blood Urea Nitrogen (mmol/L): >1.2×ULN | 14 | 27 |
| Calcium (mmol/L): >1.1×ULN | 0 | 1 |
| Chloride (mmol/L): <0.9×LLN | 1 | 1 |
| Cholesterol, Total, Fasting (mmol/L): >1.6×ULN | 2 | 5 |
| Creatinine (umol/L): >1.3×ULN | 15 | 20 |
| Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN | 22 | 52 |
| Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN | 4 | 14 |
| Glycohemoglobin A1C (%): Increase of ≥0.5% | 95 | 247 |
| Glycohemoglobin A1C (%): Increase of ≥1% | 94 | 246 |
| Phosphorus (mmol/L): >1.1×ULN | 13 | 5 |
| Phosphorus (mmol/L): <0.9×LLN | 1 | 4 |
| Potassium (mmol/L): <0.9×LLN | 1 | 0 |
| Protein, Total (g)/L): >1.1×ULN | 1 | 0 |
| Triglycerides, Fasting (mmol/L): ≥3.0×ULN | 8 | 9 |
| Uric Acid (Urate) (umol/L): >1.1×ULN | 17 | 37 |
| Uric Acid (Urate) (umol/L): <0.9×LLN | 1 | 9 |
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With Clinically Meaningful Trends for Vital Signs | 0 | 0 |
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 2 | 2 |
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HbA1c) | 94 | 246 |
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
| Participants | Relamorelin 10 μg |
|---|---|
| Screening Test (Baseline) — Negative | 127 |
| Screening Test (Baseline) — Positive | 39 |
| Confirmatory Test (Baseline) — Negative | 5 |
| Confirmatory Test (Baseline) — Positive | 0 |
| Screening Test (Day 84) — Negative | 73 |
| Screening Test (Day 84) — Positive | 23 |
| Confirmatory Test (Day 84) — Negative | 6 |
| Confirmatory Test (Day 84) — Positive | 1 |
| Screening Test (Day 364) — Negative | 10 |
| Screening Test (Day 364) — Positive | 4 |
| Confirmatory Test (Day 364) — Negative | — |
| Confirmatory Test (Day 364) — Positive | — |
| Screening Test (End of Treatment) — Negative | 20 |
| Screening Test (End of Treatment) — Positive | 6 |
| Confirmatory Test (End of Treatment) — Negative | 1 |
| Confirmatory Test (End of Treatment) — Positive | 0 |
| Screening Test (Unscheduled) — Negative | 2 |
| Screening Test (Unscheduled) — Positive | 1 |
| Confirmatory Test (Unscheduled) — Negative | 1 |
| Confirmatory Test (Unscheduled) — Positive | 0 |
Collected over First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 56 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/148 (0%) | 21/145 (14.5%) | 37/145 (25.5%) |
| Relamorelin 10 μg | 2/302 (0.7%) | 43/299 (14.4%) | 82/299 (27.4%) |
| Event | Placebo | Relamorelin 10 μg |
|---|---|---|
| PneumoniaInfections and infestations | 2/145 | 1/299 |
| FallInjury, poisoning and procedural complications | 0/145 | 3/299 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/145 | 3/299 |
| Acute left ventricular failureCardiac disorders | 1/145 | 1/299 |
| Cardiac failureCardiac disorders | 1/145 | 0/299 |
| Sinus tachycardiaCardiac disorders | 1/145 | 0/299 |
| PancreatitisGastrointestinal disorders | 1/145 | 1/299 |
| Abdominal pain upperGastrointestinal disorders | 1/145 | 0/299 |
| ConstipationGastrointestinal disorders | 1/145 | 0/299 |
| Diabetic gastroparesisGastrointestinal disorders | 1/145 | 0/299 |
| Event | Placebo | Relamorelin 10 μg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/145 | 21/299 |
| Urinary tract infectionInfections and infestations | 9/145 | 28/299 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/145 | 18/299 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/145 | 15/299 |
| HeadacheNervous system disorders | 7/145 | 15/299 |
Intent-to-treat (ITT) Population included all randomized participants.
| Age, Continuous(years) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Mean | 57.0 ± 12.37 | 57.9 ± 11.57 | 57.6 ± 11.84 |
| Sex: Female, Male(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Female | 102 | 224 | 326 |
| Male | 46 | 78 | 124 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Hispanic or Latino | 50 | 82 | 132 |
| Not Hispanic or Latino | 98 | 220 | 318 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 11 | 18 |
| Asian | 0 | 9 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 27 | 53 | 80 |
| White | 109 | 218 | 327 |
| More than one race | 4 | 11 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 349 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Nov 2020, 33 months.
Results were first posted in Nov 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relamorelin